The Soluble Plasminogen Activator Receptor as a Biomarker on Monitoring the Therapy Progress of Pulmonary TB-AFB(+) Patients
Figure 1
(a) Serum levels of soluble urokinase receptor (suPAR), (b) sedimentation rate of erythrocytes (ESR), (c) monocyte count (d) Body Mass Index (BMI) in 20 TB patient before (0), during (2 and 4 months), and after (6 months) completion of anti-TB treatment. Individual profile (dotted line) and median (thick line) levels are shown.
